
SUPPLEMENT 6

Figure 1. Inhibitory effects of Andrographis, Eleutherococcus extracts and their combination (Kan Jang) on molecular network associated with anti-inflammatory and antimicrobial response. Andrographys downregulated 11 of 28 genes lead to predicted inhibition of inflammation, only 4 genes are downregulated by Eleutherococcus, while in combination (Kan Jang) they synergistically deregulate 28 of 28 genes of inflammatory network.

* - For references see Panossian et al. 2015; https://doi.org/10.1016/j.phymed.2015.08.004



A summary of findings from pre-clinical and studies on the mechanism of action of Andrographis and Eleutherococcus that potentially have clinical significance in relieving the symptoms of upper respiratory tract infections.

Andrographis paniculata extracts and their active constituents have polyvalent actions targeting multiple mediators involved in the life cycle of viruses and bacteria and acute inflammatory host response to an infectious agent.

Polyvalent action of Andrographis includes:

- anti-inflammatory activity associated with modulation of immune response of the innate immune system by inhibition of NFk-B, platelet-activating factor (PAF) antagonism, inhibition of NO production in macrophages, inhibition of histamine and proinflammatory interleukins,
- antiviral activity (associated with the direct inhibition of replication of viruses and indirect antiviral effect via activation of the immune system, including cytokines formation)
- antibacterial activity (associated with the direct bacteriostatic and bactericide effects and indirect antimicrobial effect via activation of the innate and adaptive immune response).

The pharmacology of *A. paniculata* extracts and their active principles, primarily andrographolides I-III, has been studied in different animal models using different modes of administration (oral, intravenous, subcutaneous) and different species including mouse, rat, pigs, rabbit, dog, monkey and isolated tissues from different species, bacteria *in vitro*.

These studies have demonstrated an effect on:

- **an immune system** anti-inflammatory (including anti-pyretic, analgesic and antiallergic) effect, IFγ - mediated antibacterial and antiviral effects, NF-κB, TNF-α, IL-1, IL-2, IL-6, IL-12, COX-2, PAF, LTB₄ and NO mediated effects on the respiratory system,
- a neuroendocrine system analgesic effect,
- an infectious agent antiviral and antimicrobic effects.

Table 1. Viricidal effects

| Virus name | Eleutherococcus | Andrographis |
|-----------------------------------|-----------------------------------|-------------------------|
| | eleutherosides | andrographolies |
| SARS-COV-2 | | Asea et al., 2021 |
| human rhinovirus (HRV), | Glatthaar-Saalmuller et al., 2001 | |
| respiratory syncytial virus (RSV) | Glatthaar-Saalmuller et al., 2001 | |
| H1N1 influenza A virus | Glatthaar-Saalmuller et al., 2001 | Ding et al. 2017 |
| | Yan et al. 2018, | Yu et al., 2014 |
| | Yan et al. 2020, | Ko, Wei and Chiou 2006 |
| H5N1 avian influenza virus | | Sornpet et al, 2917 |
| Chikungunya virus | | Wintachai et al., 2015 |
| Dengue virus | | Panraksa et al., 2017; |
| | | Ramalingam et al. 2018; |

^{* -} For references see Panossian and Brendler 2020;. https://doi.org/10.3390/ph13090236

Table 2. Specific Antiviral Action: Effects on SARS virus binding to cells and replication

| | | 1 |
|---|--------------------|-----------------------|
| Target/mediator | Eleutherococcus | Andrographis |
| | eleutherosides | andrographolides |
| Effects on viral life cycle in infected host cells – targets preventing the virus RNA synthesis and replication | | |
| Nsp5: 3-chymotrypsin-like protease (3Clpro) – M ^{pro} main | Zhang et al., 2020 | Enmozhi et al., 2020; |
| protease of SARS-COV-2 | Mani et al. 2020 | Wu et al., 2020 |
| Nsp3: papain like protease (Plpro) | Zhang et al., 2020 | Wu et al., 2020 |
| | Mani et al. 2020 | |
| Nsp12: RNA-dependent RNA polymerase (RdRp) | | Wu et al., 2020 |
| Nsp1: the most N-terminal gene 1 protein | | Wu et al., 2020 |
| Targets inhibiting virus structural proteins | | |
| S2: Spike glycoprotein receptor to type-II transmembrane | | Wu et al., 2020 |
| serine protease enzymes (TMPRSS2) of host cells | | |

^{* -} For references see Panossian and Brendler 2020;. https://doi.org/10.3390/ph13090236

Table 3. Non-Specific Antiviral Action: Effects on innate and adaptive immunity

| ± | 1 | 5 | |
|---|------------------------|-------------------------|--|
| Target/mediator | Eleutherococcus | Andrographis | |
| | eleutherosides | andrographolides | |
| Innate Immunity | | | |
| Defensins peptides | | Shao, et al. 2012; | |
| Human β-defensin-2 | | Xiong et al. 2015 | |
| Pathogen's pattern recognition receptors TLR proteins | Panossian et al.,2018; | Gao and Wang, 2016; | |
| | Han et al., 2003; | Kim et al., 2018 | |
| Interferons | | Panossian et al., 2002 | |
| Interleukins: IL-6, IL-1β, IL-10, TNF etc. | Jin et al. 2020; | Chao, et al. 2011 | |
| | Panossian et al., 2003 | Panossian et al., 2003; | |
| | | Panossian et al., 2002 | |
| Melatonin signaling pathways | Panossian et al.,2018; | | |
| Adaptive immunity | | | |
| B Cells and Antibodies | Han et al., 2003; | Panossian et al., 2002 | |
| | | | |

^{* -} For references see Panossian and Brendler 2020;. https://doi.org/10.3390/ph13090236

Table 4. Anti-inflammatory effect, reparations of oxidative stress induced injuries in compromised cells and tissues

| Target/mediator | Eleutherococcus | Andrographis |
|---|-------------------------|--------------------------|
| | eleutherosides | andrographolides |
| Arachidonic acid release, inhibition of phospholipase 2 | | Kishore et al., 2016 |
| COX-2 mediated signaling | Panossian et al.,2019 | Chao, et al. 2009; |
| | | Kim et al., 2018 |
| Lipoxygenases mediated signaling of arachidonic acid pro- | Panossian et al.,2019 | |
| and anti-inflammatory metabolites leukotrienes, lipoxines, | | |
| resolvins, etc. | | |
| PAF: platelet activating factor | | Amroyan et al., 1999; |
| | | Burgos et al., 2005; |
| Nitric oxide mediated inflammation: | | |
| inducible NO synthase | Panossian et al., 2003; | Chiou, Chen and Lin 2000 |
| oxide catabolites (NOC) | Panossian et al., 2007 | Panossian et al., 2003 |
| NFkB mediated inflammation | Han et al., 2003; | Dai et al. 2019; |
| NFkB signaling, translocation and expression | | Chao, et al. 2011; |
| | | Gao and Wang, 2016; |
| | | Kim et al., 2018 |
| Nrf2-mediated Oxidative Stress Response Signaling Pathway | Wang et al., 2010 | |
| proteins: | | |
| Phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt), | | |
| KEAP1, etc. | | |
| Nrf2-ARE (antioxidant response element) -expression | | |
| Antioxidant proteins (SOD, GST, NQO1 and HO1), lipids | Wang et al., 2010; | |
| peroxidation | | |
| Molecular chaperons mediated cytoprotecting, and repairing | Panossian et al., 2007 | |
| processes Heat shock proteins Hsp72, | Asea et al., 2013; | |
| | Panossian et al., 2009 | |
| Melatonin signaling | Panossian et al.,2018 | |
| Retinoic-acid-receptor (RAR)-related orphan nuclear | | |
| receptor alpha (ROR α), | | |

^{* -} For references see Panossian and Brendler 2020;. https://doi.org/10.3390/ph13090236

A summary of findings from pre-clinical and studies

Systematic reviews of available clinical studies suggest that *A. paniculata* is significantly superior to placebo in relieving the symptoms of uncomplicated URTI and in shortening the time to symptom resolution. ¹⁹⁻²⁷ Prophylactic treatment with the *E. senticosus* extract has also been shown to reduce a number of complications associated with the influenza infection, including pneumonia, bronchitis, and otitis, as well as morbidity and mortality rates. ^{5,6}

Table 5. Clinical efficacy in respiratory tract infectious diseases

| Eleutherococcus | Andrographis | |
|---|----------------------------|--|
| EMA/HMPC, 2013; | Hancke et al. 1995; | |
| Galanova, 1977; | Caceres et al. 1999; | |
| Schezin et al., 1977; | Melchior et al. 1996; | |
| Gagarin IA, 1977; | Saxena et al. 2010 | |
| Barkan et al.,1980; | Panossian and Wikman, 2012 | |
| Shadrin et al., 1986; | | |
| Sheparev et al., 1986 | | |
| Kan Jang combination | | |
| Caceres et al. 1997; Gabrielyan et al., 2000; Melchior et al., 2000; Kulichenko et al., 2003; | | |

Spasov et al., 2004,

^{* -} For references see Panossian and Brendler 2020;. https://doi.org/10.3390/ph13090236